Rapid CRISPR Test Could Cut Deaths from Rocky Mountain Spotted Fever

When a fever pops up after a hike through grassy fields, most of us think of the flu or a simple bug. In the Midwest, however, that same fever could be a warning sign of Rocky Mountain spotted fever, a tick‑borne illness that, if missed, can be fatal—especially for kids.

Now, a team at the University of Missouri says they’ve cracked the timing problem. In a paper published in Frontiers in Microbiology (DOI 10.3389/fmicb.2026.1823193), researchers led by Curators’ Distinguished Professor Roman Ganta describe a rapid, isothermal RPA‑CRISPR/Cas12a assay that lights up in about 40 minutes. No fancy thermocyclers, no cold chain—just a simple color change you can see with the naked eye.

“We wanted something that could be done in a rural clinic, maybe even in a field lab,” Ganta explains. The test works by first amplifying any bacterial DNA present with recombinase polymerase amplification (RPA). Then the Cas12a enzyme, guided by a tiny RNA, snips a reporter molecule if the target — the DNA of Ricketria rickettsii — is there. When it does, the solution turns a vivid shade, telling the user, “yes, we’ve found the pathogen.” The whole process takes two 20‑minute steps, and the result is readable at room temperature.

Why does speed matter so much? Because the standard treatment—doxycycline—works best when started early. Delays of even a day can push mortality rates upward, and children are especially vulnerable. “A quick, reliable test means doctors can prescribe doxycycline right away, rather than waiting for a lab that might be days away,” notes Ganta.

The assay is still in the research phase. So far, it’s been validated in the university’s Veterinary Medical Diagnostic Laboratory, but external field trials haven’t been published yet. The team acknowledges that regulatory clearance, supply‑chain logistics for reagents, and real‑world testing in low‑resource settings remain hurdles before the test can roll out widely.

Still, the prospect is exciting. If the technology proves robust, it could replace the current, often expensive PCR‑based methods that many small clinics can’t afford. In the long run, faster detection could mean fewer deaths, less severe disease, and a lighter burden on public‑health systems—both here in Missouri and in tick‑endemic regions around the globe.